AroCell AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AROC.ST research report →
Companywww.arocell.com
AroCell AB (publ), a vitro diagnostics company, focuses on monitoring of hematological malignancies, breast cancer, and other solid tumors. The company develops, manufactures, and sells AroCell TK 210 ELISA, an immunoassay kit for the determination of Thymidine Kinase 1 in human blood. It also offers TUBEX TF, a bacteriological rapid test for diagnosis of typhoid fever.
- CEO
- Anders Hultman
- IPO
- 2011
- Employees
- 22
- HQ
- Uppsala, SE
Price Chart
Valuation
- Market Cap
- $132.23M
- P/E
- 72.25
- P/S
- 1.84
- P/B
- 0.67
- EV/EBITDA
- 5.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 65.15%
- Op Margin
- 5.36%
- Net Margin
- 2.54%
- ROE
- 1.03%
- ROIC
- 1.80%
Growth & Income
- Revenue
- $57.44M · 33.45%
- Net Income
- $-42,449,000 · 28.41%
- EPS
- $-0.18 · 30.77%
- Op Income
- $-43,430,000
- FCF YoY
- 83.98%
Performance & Tape
- 52W High
- $0.66
- 52W Low
- $0.35
- 50D MA
- $0.56
- 200D MA
- $0.52
- Beta
- 1.21
- Avg Volume
- 202.01K
Get TickerSpark's AI analysis on AROC.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AROC.ST Coverage
We haven't published any research on AROC.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AROC.ST Report →